Table 4.
PTLD treatment.
| LTRs | KTRs | ||
|---|---|---|---|
| PTLD Treatment | n (%) | p-Value | |
| RIS RAPA |
22 (95.7) | 14 (87.5) | 0.37 |
| 9 (39.1) | 3 (18.8) | 0.186 | |
| EVR Anti-CD20 |
0 (0) | 1 (6.3) | 0.251 |
| 6 (26.1) | 4 (25) | 0.955 | |
| Chemotherapy -R-CHOP |
14 (60.9) | 11 (68.8) | 0.631 |
| 7 (30.4) | 2 (12.5) | 0.204 | |
| -CHOP | 4 (17.4) | 2 (12.5) | 0.698 |
| -Other | 3 (13) | 7 (43.8) | 0.02 * |
| Surgery | 8 (34.8) | 5 (31.3) | 0.834 |
| Radiotherapy | 0 (0) | 2 (12.5) | 0.093 |
Chemotherapy—combined instances R-CHOP, CHOP, and other use, EVR—conversion to everolimus, KTRs—kidney transplant recipients, LTRs—liver transplant recipients, Other—chemotherapy protocols less frequently used in PTLD (e.g., doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), ifosfamide, carboplatin, etoposide (ICE), cyclophosphamide monotherapy), RAPA—conversion to sirolimus, RIS—reduction of immunosuppression, R-CHOP—anti-CD20 + CHOP. p-values represent the Mann–Whitney U-test comparison between KTRs and LTRs. * p < 0.05.